DDInter1263 DDInter927
Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence.
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Naltrexone {u} may lead to a major life threatening interaction when taken with {v} Oxycodone
Naltrexone {u} (Compound) resembles {v} (Compound) Hydrocodone
Naltrexone {u} (Compound) resembles {v} (Compound) Butorphanol
Naltrexone {u} (Compound) treats {v} (Disease) alcohol dependence
Naltrexone {u} (Compound) binds {v} (Gene) OPRD1
Naltrexone {u} (Compound) upregulates {v} (Gene) TSC22D3
Naltrexone {u} (Compound) is included by {v} (Pharmacologic Class) Opioid Antagonists
Naltrexone {u} (Compound) downregulates {v} (Gene) IER3
Naltrexone {u} (Compound) causes {v} (Side Effect) Dyspnoea
Naltrexone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Chlorzoxazone
Naltrexone may lead to a major life threatening interaction when taken with Oxycodone
Naltrexone (Compound) resembles Hydrocodone (Compound)
Naltrexone (Compound) resembles Butorphanol (Compound)
Naltrexone (Compound) treats alcohol dependence (Disease)
Naltrexone (Compound) binds OPRD1 (Gene)
Naltrexone (Compound) upregulates TSC22D3 (Gene)
Naltrexone (Compound) is included by Opioid Antagonists (Pharmacologic Class)
Naltrexone (Compound) downregulates IER3 (Gene)
Naltrexone (Compound) causes Dyspnoea (Side Effect)
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Chlorzoxazone